Pfizer CMO Freda Lewis-Hall On The New R&D Shift: An Interview With PharmAsia News (Part 1 of 2)
This article was originally published in PharmAsia News
A senior Pfizer executive pushes the theme of large collaborations by stakeholders globally to spur innovation and productivity.
You may also be interested in...
An NME Surge After The Patent Cliff? Reinvention Of R&D Starts Paying Off In 2013 New Product Candidates
With almost 40 novel agents already pending at FDA, 2013 looks like a good bet to repeat the strong NME and novel biologic approval counts of 2012 and 2011. Big pharma and big markets dominate the 2013 slate so far, especially with diabetes, respiratory and central nervous system candidates.
Pfizer Chief Medical Officer Freda Lewis-Hall, a member of the Patient-Centered Outcomes Research Institute’s Board of Governors, talked to “The Pink Sheet” DAILY about the institute’s work over the past two years and coming up in 2013 and how the institute and the pharmaceutical industry have interacted since PCORI was set up by the Affordable Care Act.
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.